Contemporary use of guideline‐based higher potency P2Y12 receptor inhibitor therapy in patients with moderate‐to‐high risk non‐ST‐segment elevation myocardial infarction: Results from the Canadian ACS reflective II cross‐sectional study

Background After myocardial infarction, guidelines recommend higher‐potency P2Y12 receptor inhibitors, namely ticagrelor and prasugrel, over clopidogrel. Hypothesis We aimed to determine the contemporary use of higher‐potency antiplatelet therapy in Canadian patients with non‐ST‐elevation myocardial...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cardiology (Mahwah, N.J.) N.J.), 2021-06, Vol.44 (6), p.839-847
Hauptverfasser:	Patel, Ashish, Goodman, Shaun G., Tan, Mary, Suskin, Neville, McKelvie, Robert, Mathew, Andrew L., Lutchmedial, Sohrab, Dehghani, Payam, Lavoie, Andrea J., Huynh, Thao, Lavi, Shahar, Philipp, Roger, Khan, Razi, Yan, Andrew T., Radhakrishnan, Sam, Sedlak, Tara, Brunner, Nathan, Kim, Hahn Hoe, Cieza, Tomas, Kassam, Saleem, Fordyce, Christopher B., Heffernan, Michael, Jedrzkiewicz, Sean, Madan, Mina, Ahmed, Shaheeda, Barry, Colin, Dery, Jean‐Pierre, Bagai, Akshay
Format:	Artikel
Sprache:	eng
Schlagworte:	acute coronary syndrome Acute coronary syndromes Age Aggregation Apixaban Atrial fibrillation Biomarkers Blood platelets Blood transfusions Cardiac arrhythmia Cardiology Cardiovascular disease Care and treatment Clinical Investigations Coronary vessels Cross-sectional studies Diabetes Heart attacks Heart failure Heart surgery Hospitalization Hypertension Patients pharmacology Physicians Population Rivaroxaban Stroke Thrombosis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!